# EDGAR Filing Document

**Accession Number:** 0002142869
**File Stem:** 0001213900-26-073067
**Filing Date:** 2026-6
**Character Count:** 10236
**Document Hash:** 0b1ecbeb1e4adbebb5bd7a154eb9a6bf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-073067.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001213900-26-073067

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260625

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Miyara Faical
- **CENTRAL INDEX KEY:** 0002142869

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42484
- **FILM NUMBER:** 261135350

**MAIL ADDRESS:**
- **STREET 1:** C/O ASCENTAGE PHARMA GROUP INC.
- **STREET 2:** 700 KING FARM BOULEVARD, SUITE 510
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASCENTAGE PHARMA GROUP INTERNATIONAL
- **CENTRAL INDEX KEY:** 0002023311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 68 XINQING ROAD
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** SUZHOU , JIANGSU
- **PROVINCE COUNTRY:** F4
- **BUSINESS PHONE:** 86 512 8555 7777

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 68 XINQING ROAD
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** SUZHOU , JIANGSU
- **PROVINCE COUNTRY:** F4

## Ex-24

```
<pre>
      POWER OF ATTORNEY

The undersigned hereby makes, constitutes and appoints each of Leslie Brault,
acting singly, and with full power of substitution, re-substitution and
delegation, the undersigned's true and lawful attorney in fact (each of such
persons and their substitutes and delegees being referred to herein as the
"Attorney-in-Fact"),
with full power to act for the undersigned and in the undersigned's name, place
and stead, in the undersigned's capacity as an officer, director or stockholder
of Ascentage Pharma Group International (the "Company"), to:

1. Take such actions as may be necessary or appropriate to enable the
undersigned to submit and file forms, schedules and other documents with the
U.S. Securities and Exchange Commission ("SEC") utilizing the SEC's Electronic
Data Gathering and Retrieval ("EDGAR") system, which actions may include (a)
enrolling the undersigned in EDGAR Next and (b) preparing, executing and
submitting to the SEC a Form ID, amendments thereto, and such other documents
and information as may be necessary or appropriate to obtain codes and passwords
enabling the undersigned to make filings and submissions
utilizing the EDGAR system;

2. Prepare and execute any and all forms, schedules and other documents
(including any
amendments thereto) the undersigned is required to file with the SEC, or which
the Attorney-in-Fact considers it advisable for the undersigned to file with the
SEC, under Section 13 or Section 16 of the Securities Exchange Act of 1934 or
any rule or regulation thereunder, or under Rule 144 under the Securities Act of
1933 ("Rule 144"), including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms
144 (all such
forms, schedules and other documents being referred to herein as "SEC Filings");

3. Submit and file SEC Filings with the SEC utilizing the EDGAR system or cause
them to
be submitted and filed by a person appointed under Section 5 below;

4. File, submit or otherwise deliver SEC Filings to any securities exchange on
which the Company's securities may be listed or traded;

5. Act as an account administrator for the undersigned's EDGAR account,
including: (i)
appoint, remove and replace account administrators, account users, technical
administrators and delegated entities; (ii) maintain the security of the
undersigned's EDGAR account, including modification of access codes; (iii)
maintain, modify and certify the accuracy of information on the undersigned's
EDGAR account dashboard; (iv) act as the EDGAR point of contact with respect to
the undersigned's EDGAR account; and
(v) any other actions contemplated by Rule 10 of Regulation S-T with respect to
account administrators;

6. Cause the Company to accept a delegation of authority from any of the
undersigned's
EDGAR account administrators and, pursuant to that delegation, authorize the
Company's EDGAR account administrators to appoint, remove or replace users for
the undersigned's EDGAR account; and

7. Obtain, as the undersigned's representative and on the undersigned's behalf,
information regarding transactions in the Company's equity securities from any
third party, including the Company and any brokers, dealers, employee benefit
plan administrators and trustees, and the undersigned hereby authorizes any such
third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:
a. This Power of Attorney authorizes, but does not require, the Attorney-in-Fact
to
act in his or her discretion on information provided to such Attorney-in-Fact
without independent verification of such information;
b. Any documents prepared or executed by the Attorney-in-Fact on behalf of the
undersigned pursuant to this Power of Attorney will be in such form and will
contain such information as the Attorney-in-Fact, in his or her discretion,
deems necessary or desirable;
c. Neither the Company nor the Attorney-in-Fact assumes any liability for the
undersigned's responsibility to comply with the requirements of Section 13 or
Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for
any failure to comply with such requirements, or any liability of the
undersigned for disgorgement of profits under Section 16(b) of the Exchange Act;
and
d. This Power of Attorney does not relieve the undersigned from responsibility
for
compliance with the undersigned's obligations under Section 13 or Section 16 of
the Exchange Act, including, without limitation, the reporting requirements
under Section 13 or Section 16 of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority
to do and perform each and every act and thing requisite, necessary or advisable
to be done in connection with the foregoing, as fully, to all intents and
purposes, as the undersigned might or could do in person, hereby ratifying and
confirming
all that the Attorney-in-Fact, or his or her substitute or substitutes, shall
lawfully do or cause to be done by authority of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G
or Forms 144 with respect to the undersigned's holdings of and transactions in
securities of the Company, unless earlier revoked by the undersigned in a signed
writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all
previous powers of attorney with
respect to the subject matter of this Power of Attorney.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of
June 26, 2026.

/S/Faical Miyara

State of Florida
County of Orange
This Power of Attorney was acknowledged before me on June 26, 2026 by Faical
Miyara.

/S/ Maggie Fung
Notary Signature

[Notary Seal]
    </pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Miyara Faical<br><sub>(Last) (First) (Middle)</sub><br>C/O ASCENTAGE PHARMA GROUP INC.<br>700 KING FARM BOULEVARD, SUITE 510<br><sub>(Street)</sub><br>ROCKVILLE, MD 20850<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-06-25 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Business Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
This form is filed using a special power of attorney.

**Signature:** Thomas J. Knapp  
**Date:** 2026-06-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**